2,5-Bis-<2-carboxy-ethyl>-3,6-dioxo-piperazin | 6437-35-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,5-Bis-<2-carboxy-ethyl>-3,6-dioxo-piperazin
• 英文别名: 3,6-Bis--2,5-diketo-piperazin；3,3'-(3,6-dioxo-piperazine-2,5-diyl)-bis-propionic acid；3,3'-(3,6-Dioxopiperazine-2,5-diyl)dipropanoic acid；3-[5-(2-carboxyethyl)-3,6-dioxopiperazin-2-yl]propanoic acid
• CAS: 6437-35-0
• 化学式: C₁₀H₁₄N₂O₆
• 分子量: 258.231
• InChiKey: NDCKGUDRHBPJAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Microparticles comprising diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
  申请人：MannKind Corporation

  公开号：EP2314298A1

  公开（公告）日：2011-04-27

  Microparticles comprising a pharmaceutically acceptable salt of a heterocyclic compound and a biologically active agent, wherein said microparticles release said biologically active agent, and said heterocyclic compound has the structure according to Formula 1: wherein R1 or R2 comprise at least one carboxylate functional group; E1 and E2 are either N or O; and said salt further comprises at least one cation.

  由杂环化合物的药学上可接受的盐和生物活性剂组成的微粒，其中所述微粒释放所述生物活性剂，所述杂环化合物具有符合式 1 的结构： 其中 R1 或 R2 包含至少一个羧酸官能团； E1 和 E2 是 N 或 O；以及 所述盐还包括至少一种阳离子。
• Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
  申请人：MannKind Corporation

  公开号：EP2322180A1

  公开（公告）日：2011-05-18

  A pharmaceutically-acceptable salt of a heterocyclic compound according to Formula 1: wherein R1 or R2 comprise at least one carboxylate functional group; E1 and E2 are either N or O; said salt further comprises at least one cation; and wherein said salt is not a lithium salt of 2,5-diaspartyl-3,6-diketopiperazine or 2,5-diglutamyl-3,6-diketopiperazine and said salt is in a solid form.

  符合式 1 的杂环化合物的药学上可接受的盐： 其中 R1 或 R2 包含至少一个羧酸官能团； E1 和 E2 是 N 或 O； 所述盐还包括至少一个阳离子；以及 其中所述盐不是 2,5-二天冬氨酰-3,6-二酮哌嗪或 2,5-二谷氨酰-3,6-二酮哌嗪的锂盐，且所述盐为固体形式。
• Diketopiperazine salts for drug delivery and related methods
  申请人：MannKind Corporation

  公开号：US10912821B2

  公开（公告）日：2021-02-09

  Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.

  在形成二酮哌嗪羧酸盐和含有二酮哌嗪羧酸盐的微颗粒的基础上，开发出了药物输送系统。这些系统可进一步包含生物活性剂。还提供了制造和使用生物活性剂递送组合物的相关方法。在某些实施方案中，所述的药学上可接受的盐可以通过蒸馏、蒸发、喷雾干燥或冻干等方法去除溶剂形成。
• DIKETOPIPERAZINE SALTS, DIKETOMORPHOLINE SALTS OR DIKETODIOXANE SALTS FOR DRUG DELIVERY
  申请人：Mannkind Corporation

  公开号：EP1791542A1

  公开（公告）日：2007-06-06
• Microparticles comprising diketopiperazine salts for drug delivery
  申请人：MannKind Corporation

  公开号：EP2314298B1

  公开（公告）日：2015-05-27